Status:
COMPLETED
Oral Curcumin Administration to Remit Metabolic Syndrome
Lead Sponsor:
Coordinación de Investigación en Salud, Mexico
Conditions:
Metabolic Syndrome
Eligibility:
All Genders
20-55 years
Phase:
NA
Brief Summary
The metabolic syndrome consists of a set of risk factors that increases the probability to develop heart diseases and type 2 diabetes, two of the principal chronic diseases that affect Mexican populat...
Detailed Description
Objective: The aim of this study is to determinate the efficacy of oral administration of curcumin in the remission of metabolic syndrome. Design: clinical trial, randomized, double blind, placebo co...
Eligibility Criteria
Inclusion
- Women and men.
- 20 to 55 years old.
- Diagnosis of metabolic syndrome according to the ATP III criteria.
- Informed consent of the participant.
Exclusion
- Diabetes or hypoglycaemic therapy.
- High blood pressure o anti-hypertensive treatments.
- Hypertriglyceridemia (\>400 g/dL) or lipid lowering treatment.
- Neoplasia disease.
- Thyroid disease
- Syndrome of polycystic ovary.
- Pregnancy or lactation.
- Smoking.
- Anti-inflammatory medicines in the last two months.
- Food supplements in the last two months.
Key Trial Info
Start Date :
May 6 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 6 2019
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT03795792
Start Date
May 6 2018
End Date
December 6 2019
Last Update
April 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Biomedical Research Unit. IMSS. Durango
Durango, Durango, Mexico, 34067